CN116437906A - 曲前列环素前药的干粉组合物和其使用方法 - Google Patents
曲前列环素前药的干粉组合物和其使用方法 Download PDFInfo
- Publication number
- CN116437906A CN116437906A CN202180072519.9A CN202180072519A CN116437906A CN 116437906 A CN116437906 A CN 116437906A CN 202180072519 A CN202180072519 A CN 202180072519A CN 116437906 A CN116437906 A CN 116437906A
- Authority
- CN
- China
- Prior art keywords
- dry powder
- powder composition
- compound
- formula
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063106818P | 2020-10-28 | 2020-10-28 | |
| US63/106,818 | 2020-10-28 | ||
| PCT/US2021/057078 WO2022094100A1 (en) | 2020-10-28 | 2021-10-28 | Dry powder compositions of treprostinil prodrugs and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116437906A true CN116437906A (zh) | 2023-07-14 |
Family
ID=81384296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180072519.9A Pending CN116437906A (zh) | 2020-10-28 | 2021-10-28 | 曲前列环素前药的干粉组合物和其使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20240285570A1 (https=) |
| EP (1) | EP4236934A4 (https=) |
| JP (1) | JP2023548307A (https=) |
| KR (1) | KR20230096998A (https=) |
| CN (1) | CN116437906A (https=) |
| AU (1) | AU2021369679A1 (https=) |
| CA (1) | CA3196252A1 (https=) |
| MX (1) | MX2023004812A (https=) |
| WO (1) | WO2022094100A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2860975T3 (es) | 2013-10-25 | 2021-10-05 | Insmed Inc | Compuestos de prostaciclina |
| CN114072136B (zh) | 2019-04-29 | 2024-11-29 | 英斯梅德股份有限公司 | 曲前列素前药的干粉组合物及其使用方法 |
| AU2024371435A1 (en) | 2023-10-30 | 2026-04-23 | Insmed Incorporated | Medicament delivery device, cover, and methods of medicament delivery |
| WO2025147662A1 (en) * | 2024-01-04 | 2025-07-10 | Insmed Incorporated | Methods of treatment using dry powder compositions of treprostinil prodrugs |
| WO2025230917A1 (en) * | 2024-04-29 | 2025-11-06 | Pharmosa Biopharm Inc. | Methods for treating systemic sclerosis and frost bite by inhalation therapy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101780092A (zh) * | 2003-05-22 | 2010-07-21 | 联合治疗公司 | 化合物和释放前列环素类似物的方法 |
| WO2019237028A1 (en) * | 2018-06-07 | 2019-12-12 | Mannkind Corporation | Composition and method for inhalation |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1016489B (it) | 1974-03-18 | 1977-05-30 | Isf Spa | Inalatore |
| IT1240750B (it) | 1990-04-12 | 1993-12-17 | Chiesi Farma Spa | Dispositivo per la somministrazione di sostanze medicamentose in polvere |
| GB9015522D0 (en) | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| DK0674533T3 (da) | 1992-12-18 | 1999-09-27 | Schering Corp | Inhalator for medikamenter i pulverform |
| GB9306703D0 (en) | 1993-03-31 | 1993-05-26 | Fisons Plc | Inhalation device |
| SE9302550D0 (sv) | 1993-07-30 | 1993-07-30 | Ernst Hoerlin | Powder inhaler |
| PT101450B (pt) | 1994-02-02 | 1999-11-30 | Hovione Produtos Farmaceuticos | Novo dispositivo para inalacao |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| FI95441C (fi) | 1994-05-31 | 1996-02-12 | Leiras Oy | Inhalointilaitteen lääkeainekammio |
| FR2725626A1 (fr) | 1994-10-18 | 1996-04-19 | Sofab | Dispositif pour l'inhalation de produits en poudre |
| SE9404439D0 (sv) | 1994-12-21 | 1994-12-21 | Astra Ab | Inhalation device |
| ES2216418T3 (es) | 1995-12-07 | 2004-10-16 | Jago Research Ag | Boquilla para un inhalador para la administracion de varias dosis de un polvo seco farmacologico. |
| US5797392C1 (en) | 1996-01-22 | 2001-01-09 | Direct Haler As | Inhaler |
| US6026809A (en) | 1996-01-25 | 2000-02-22 | Microdose Technologies, Inc. | Inhalation device |
| AU5719798A (en) | 1996-12-31 | 1998-07-31 | Inhale Therapeutic Systems, Inc. | Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
| PT101988B (pt) | 1997-04-04 | 2004-02-27 | Hovione Farmaciencia Sa | Sistema de orientacao e posicionamento de um objecto |
| GB9805102D0 (en) | 1998-03-10 | 1998-05-06 | Ciba Geigy Ag | Device |
| US6257233B1 (en) | 1998-06-04 | 2001-07-10 | Inhale Therapeutic Systems | Dry powder dispersing apparatus and methods for their use |
| WO1999066903A2 (en) | 1998-06-24 | 1999-12-29 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| CA2341624C (en) | 1998-08-25 | 2008-12-02 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
| IT1309592B1 (it) | 1999-03-05 | 2002-01-24 | Chiesi Farma Spa | Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e |
| ATE363892T1 (de) | 1999-03-05 | 2007-06-15 | Chiesi Farma Spa | Verbesserte pulverformulierungen zur inhalation |
| ITMI991582A1 (it) | 1999-07-16 | 2001-01-16 | Chiesi Farma Spa | Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala |
| CA2400349C (en) | 2000-03-10 | 2009-11-10 | University Of North Carolina At Chapel Hill | Dry powder inhaler devices, multi-dose dry powder drug packages, control systems, and associated methods |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| US6766799B2 (en) | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
| US6848197B2 (en) | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
| US20040102469A1 (en) | 2002-09-13 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for reducing the mortality rate |
| GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
| US7763280B2 (en) | 2002-11-28 | 2010-07-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
| ES2289221T3 (es) | 2003-10-06 | 2008-02-01 | BANG & OLUFSEN MEDICOM A/S | Inhalador. |
| US8496002B2 (en) | 2007-06-12 | 2013-07-30 | Civitas Therapeutics, Inc. | Powder inhaler devices |
| ES2860975T3 (es) * | 2013-10-25 | 2021-10-05 | Insmed Inc | Compuestos de prostaciclina |
| IL262720B2 (en) * | 2016-05-05 | 2024-06-01 | Liquidia Tech Inc | Dry powder treprostinil for the treatment of pulmonary hypertension |
| MX2019006938A (es) * | 2016-12-14 | 2019-09-06 | Respira Therapeutics Inc | Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon. |
| CN114072136B (zh) | 2019-04-29 | 2024-11-29 | 英斯梅德股份有限公司 | 曲前列素前药的干粉组合物及其使用方法 |
| US20240238309A1 (en) * | 2020-03-25 | 2024-07-18 | Insmed Incorporated | Pharmaceutical formulations of treprostinil prodrugs and methods of use thereof |
-
2021
- 2021-10-28 WO PCT/US2021/057078 patent/WO2022094100A1/en not_active Ceased
- 2021-10-28 EP EP21887529.2A patent/EP4236934A4/en active Pending
- 2021-10-28 CA CA3196252A patent/CA3196252A1/en active Pending
- 2021-10-28 MX MX2023004812A patent/MX2023004812A/es unknown
- 2021-10-28 US US18/034,619 patent/US20240285570A1/en active Pending
- 2021-10-28 KR KR1020237013241A patent/KR20230096998A/ko active Pending
- 2021-10-28 AU AU2021369679A patent/AU2021369679A1/en active Pending
- 2021-10-28 CN CN202180072519.9A patent/CN116437906A/zh active Pending
- 2021-10-28 JP JP2023526131A patent/JP2023548307A/ja active Pending
-
2023
- 2023-11-17 US US18/513,377 patent/US20240122889A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101780092A (zh) * | 2003-05-22 | 2010-07-21 | 联合治疗公司 | 化合物和释放前列环素类似物的方法 |
| WO2019237028A1 (en) * | 2018-06-07 | 2019-12-12 | Mannkind Corporation | Composition and method for inhalation |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3196252A1 (en) | 2022-05-05 |
| WO2022094100A1 (en) | 2022-05-05 |
| AU2021369679A1 (en) | 2023-05-18 |
| US20240285570A1 (en) | 2024-08-29 |
| KR20230096998A (ko) | 2023-06-30 |
| JP2023548307A (ja) | 2023-11-16 |
| US20240122889A1 (en) | 2024-04-18 |
| EP4236934A4 (en) | 2024-10-02 |
| MX2023004812A (es) | 2023-07-06 |
| EP4236934A1 (en) | 2023-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116437906A (zh) | 曲前列环素前药的干粉组合物和其使用方法 | |
| JP7732017B2 (ja) | トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法 | |
| Scheuch et al. | Novel approaches to enhance pulmonary | |
| JPH10509431A (ja) | 表面活性物質の分泌不足に関連する肺疾患の治療法 | |
| Silkstone et al. | Relative lung and total systemic bioavailability following inhalation from a metered dose inhaler compared with a metered dose inhaler attached to a large volume plastic spacer and a jet nebuliser | |
| US9539248B2 (en) | Agent for ameliorating chronic obstructive pulmonary disease | |
| CN121487728A (zh) | 喷雾干燥的曲前列环素制剂 | |
| WO2025147662A1 (en) | Methods of treatment using dry powder compositions of treprostinil prodrugs | |
| WO2025096521A1 (en) | Medicament delivery device, cover, and methods of medicament delivery | |
| Byrne et al. | Delivered Dose Efficiency of Conventional Jet Nebulizers-Does It Allow Comparison of the Likely Effective Performance? | |
| Brock et al. | Clinical considerations in the use of inhalation delivery devices |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |